AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06790537 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: placebo capsule will be identical in appearance to the pregabalin capsule. it will be given at the same time of the day like pregabalin. same Emollient which is used in the Intervention arm will be applied locally on the areas of itching, morning after bathing .
Study NCT06778174 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: The interventions are not determined by the study, which is purely observational on real world data.
Study NCT04736199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: Coated tablet, oral administration
Study NCT04736199 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Coated tablet matching Darolutamide in appearance, oral administration
Study NCT04736199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product F with 1.5% nicotine
Description: P1213816, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05213338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wear-documentation microchip
Description: Microchip embedded in the appliance
Study NCT06314789 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: doing lung ultrasonography
Description: In the study, both LUS imaging and scoring will be performed in the delivery room within the first 30 minutes and LUS score evaluation will be performed at postnatal 2nd, 6th and 24th hours in the intensive care unit for inpatients and in the maternal ward for maternal patients.
Study NCT05875792 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EvolvRehab - MoveWell
Description: The Intervention has been developed and has a CE mark and has medical device level 1 approvals in the UK. It will be developed with patients in Phase 1 and will consist of initial staff training \[training package\]. Exercise prescription will be encouraged, in line with usual care, for the either one week (stage 1, phase 2) or six weeks (stage 2, phase 2). Individuals will be able to continue using the EvolvRehab - MoveWell system beyond 6 weeks from stage 2, phase 2, and technical support will continue until the end of the study completion, participants will not be limited in the additional activity that can be performed during this time, and encouraged to do as much as they wish, except if needed for clinical reasons. The intervention will be supported by the clinical team in keeping with routine care. The research therapist will attend clinical visits and support as required. The number of visits will be recorded, and will hopefully reduce to zero over the study.
Study NCT04938323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCG Vaccine
Description: .1 mL of reconstituted BCG vaccine given intradermally at baseline.
Study NCT04938323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: .1 mL of diluent (saline) given intradermally at baseline
Study NCT05933980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rego+Tori+Cele
Description: combination of Toripalimab,regorafenib and celecoxib
Study NCT05445674 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Plasma Exchange Procedure
Description: Plasma exchanges will be performed with 5% albumin as the replacement fluid. The typical schedule prescribed will be an exchange of 1 volemia. Blood will be separated into cells and plasma; the cells will be combined with reconstituted 5% human serum albumin and reinfused into the patient with normal saline
Study NCT05445674 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Plasma Exchange Procedure
Description: For sham plasma exchange procedures, a sound behind the curtain will be performed imitating the sound of the cell processing platform. In these cases, only one infusion of 200 to 250ml of sterile saline solution 0.9% will be performed during the time stablished for all procedures. Albumin will not be necessary for those patients in the Sham plasma exchange arm
Study NCT05410483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Hyperthermic Intraperitoneal Docetaxel
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product G with 1.5% nicotine
Description: P1211916, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT04736199 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Androgen deprivation therapy (ADT)
Description: Luteinizing hormone-releasing hormone (LHRH) agonist/antagonists or orchiectomy
Study NCT04770753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching Mitapivat
Description: Tablets
Study NCT04905485 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VIOME Precision Nutrition Program
Description: Precision diet and supplement recommendations based on participants' microbiome results.
Study NCT04861389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial access
Description: Arterial access for primary percutaneous coronary intervention in STEMI patients
Study NCT04861389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial access
Description: Arterial access for primary percutaneous coronary intervention in STEMI patients
Study NCT05239884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS Product H with 1.5% nicotine
Description: P1210016, an Electronic Nicotine Delivery System (ENDS) with 1.5% nicotine
Study NCT05367401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sabatolimab
Description: Solution for intravenous infusion
Study NCT04770753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitapivat
Description: Tablets
Study NCT04770753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitapivat
Description: Tablets
Study NCT05810051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Description: The patients in this arm will be trained for 1 hour, 2 or 3 times per week for 36 sessions. In addition to the training program, the patients also get access to the cardiovascular educational program.~The training (a 1h session) consists of 60% cardiovascular endurance training and 40% resistance training.
Study NCT05367401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Solution for intravenous infusion
Study NCT05367401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Solution for subcutaneous injection or intravenous infusion
Study NCT04464577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Specified Dose on Specified Days
Study NCT04464577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Specified Dose on Specified Days
Study NCT04464577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified Dose on Specified Days
Study NCT04464577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986235
Description: Specified Dose on Specified Days
Study NCT05243719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADP101
Description: Active dry powder formulation at various volumes.
Study NCT05455814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shambhavi Madamudra Kriya
Description: The intervention is taught at the Inner Engineering program offered by non-profit Isha Foundation as online as well as in-person formats. It incorporates a combination of different breathing patterns and meditative components. The intervention training provides precise, step by step and easy to follow instructions on how to perform this practice. Performed in a seated posture, this is a simple, safe and accessible intervention that requires no previous experience of meditation. The intervention selected for this study was shown to significantly reduce perceived stress, enhance self-reported general well-being, improve positive emotions, mindfulness, sleep, engagement, relationships, and may promote enhanced Heart Rate Variability and Sympathovagal balance.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by (IV) vein
Study NCT05483660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
Study NCT05483660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
Study NCT05483660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum + Bacillus coagulans
Description: 1.5×10\^10 CFU probiotics and adult milk powder 15g per time , three times daily and half an hour before meal.
Study NCT04706091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: 10-mg or 20-mg suvorexant capsules
Study NCT05483660 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adult milk powder 15 g pertime, three times daily and half an hour before meal.
Study NCT04594018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finlândia Association + finasteride placebo
Description: Finlândia association hair lotion + finasteride placebo
Study NCT04594018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil + finasteride
Description: Minoxidil hair lotion + Finasteride 1 mg
Study NCT05141357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBI-8000 in combination with pembrolizumab
Description: Participants will take 30 mg of HBI-8000 by mouth every 3-4 days on a twice weekly (BIW) schedule. Pembrolizumab will be administered at 400 mg IV every 6 weeks (Q6W) or 200 mg IV every 3 weeks (Q3W) according to Prescribing Information and institution's prescribing practice for pembrolizumab.
Study NCT04706091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules
Study NCT06278155 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social relation training with social robot
Description: The protocol is divided in two sections: basic and advanced social relations.~The basic social relationssection consists of 4 stages:~Stage 1 focuses on spontaneous eye contact between the child and the robot Strage 2 introduces the goal of spontaneously looking at a peer Stage 3 focuses on respecting the turn between children Stage 4 aims to encourage peer cooperation Nao social robot helps children to develop specific social skills.~The advanced social relation section consists of 5 stages:~Stage 1: The goal is to initiate physical interaction with a peer during a game Stage 2 is focused on mand (verbal requests) directed to peers Stage 3: The goal is to respond spontaneously to questions or statements from peers In the Stage 4 the child should to play with peers for at least 5 minutes Stage 5: the goal is to conduct at least 4 verbal exchanges on a given topic with peers At each stage, Nao provides verbal prompts to guide the child toward the appropriate response
Study NCT06278155 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional social relations training
Description: Traditional social relations training is the same as the experimental one, however in this context the entire protocol is conducted without the aid of social robot NAO.
Study NCT05241938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSLT
Description: PSLT will be performed under topical anesthesia (proxymetacaine hydrochloride 5mg/ml eye drops) using a mirrored gonioscopy lens (Latina Ocular Instruments). A α2 agonist hypotensive eye drops (0.2% brimonidine tartrate) and 2% pilocarpine eye drops are applied 40 minutes before the procedure. After laser treatment, the patient will be instructed to use non-steroidal anti-inflammatory eye drops (thrice daily for 7 days).
Study NCT05241938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prostaglandin analogue eye drops
Description: Prostaglandin analogue eye drops will be prescribed to be used continuously once a day in the fellow eye.
Study NCT03454997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training including in-person and online
Description: training, motivational interviewing practice
Study NCT03454997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: organizational strategy meetings
Description: meetings with leadership to optimize implementation of evidence-based practices
Study NCT03454997 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: performance coaching
Description: to enhance ability to deliver the weight management intervention
Study NCT04746157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse intervention
Description: Patients will undergo an individualized patient care plan conducted by a lead nurse. According to their results on the Stroke Riskometer and their cardiovascular risk factors, the nurse will prepare a phone call for the next two weeks with information and support adapted to each patient and their necessities. Phone calls will be repeated monthly until the sixth month, then, one more the ninth month and one last previous to the end of the treatment. Patients will be able to contact the reference nurse whenever they would need to.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given by (IV) vein
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given by (IV) vein
Study NCT06115057 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Subjects in this study are to consume the study product twice daily during regular meals.~The fiber mix consists of different types of dietary fiber that are individually well tolerated for human consumption.
Study NCT05678088 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Exercises
Description: The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
Study NCT05678088 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oropharyngeal Exercises
Description: The participant will practice exercises designed to strengthen the tongue and pharyngeal muscles
Study NCT05678088 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Exercises
Description: The participant will practice exercises that have no impact on oropharyngeal (e.g., base of the tongue) muscle strength.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given by (IV) vein
Study NCT05369377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib 80mg po qd 6 weeks
Study NCT05369377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
Study NCT05369377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: eltrombopag 50 mg qd for up to 6 weeks. The eltrombopag dose could be increased from 50 mg to 75 mg after 3 weeks in patients whose platelet counts were less than 50 000 per μL. Treatment was discontinued in patients who attained a platelet count greater than 200 000 per μL.
Study NCT05087368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1-S COVID-19 Vaccine(Fiocruz/Oxford-AstraZeneca)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
Study NCT05087368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoronaVac (Sinovac Biotech)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
Study NCT05087368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Recombinant SARS-CoV-2 TrimericS-protein Subunit Vaccine (SCB-2019 - Clover)
Description: Heterologous and Homologous Vaccination Series with ChAdOx1-S or CoronaVac COVID-19 Vaccines and Various Formulations of Clover Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (SCB-2019) in Adults
Study NCT05059600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZULRESSO®
Description: Intravenous infusion of ZULRESSO®.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given by (IV) vein
Study NCT05207644 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 30 mg letrozole followed by 800 mcg misoprostol
Description: 30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3
Study NCT04495530 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: semi-structured interviews will take place on one occasion with participants in this study. This is qualitative research, and does not involve any interventions
Study NCT06269757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized Exercise Program
Description: The individualized exercise program involves an initial 2D individual running evaluation designed for runners of all ages and abilities, to help improve performance and prevent injury. During the assessment patients receive a one-on-one evaluation with an exercise physiologist that includes:~* Running analysis;~* Training program review;~* Strength and flexibility assessment;~* Review of running video;~* Personalized final report.
Study NCT06269757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Standard of care physical therapy for ITB band syndrome involves exercises designed to target structural weaknesses such as hip abductor weakness. Typical exercises include but are not limited to hip flexor stretches, side lying hip abduction, figure 4 bridges, lateral walks with exercise bands, and side planks.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given by (IV) vein
Study NCT05763108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: genetic test
Description: COL1A1 or COL5A1 genetic test
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by PO
Study NCT05763108 — intervention group
Intervention type: OTHER
Intervention: Beighton joint laxity test
Description: Based on Beighton scale.
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given by (IV) vein
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: Given by (IV) vein
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by (IV) vein
Study NCT05645718 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given by (IV) vein
Study NCT05111210 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Blood will be collected in tubes heparinés BD (Vacutainer), homogenised, and immediately transported at room temperature to Institut Pasteur to be further processed
Study NCT05111210 — intervention group
Intervention type: OTHER
Intervention: Data collection
Description: collection of socio-demographic, clinical and biological data.
Study NCT05111210 — intervention group
Intervention type: OTHER
Intervention: skin biopsies
Description: skin biopsies of 4 mm in diameter. These samples will not be taken on the face or in an area of skin folds
Study NCT06273605 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Egg Ladder
Description: 12 month protocol of graded and gradual egg introduction
Study NCT05579743 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote wound monitoring technology
Description: Healthy.io developed a professional-user wound management system that captures wound measurements and analyzes tissue distribution in real time through a smartphone application. Clinical oversight of the healing status of the wound via remote imaging and expert review allows for real time intervention when stagnation or worsening of a wound is detected. Patients with wounds on their legs will receive access to Healthy.io's mobile app and will be able to perform self-scans of their wound which will be automatically sent to the medical professionals, thus allowing them to assess the wound remotely.
Study NCT06221072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMT103
Description: 120 mg by subcutaneous injection every 4 weeks
Study NCT06221072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg by intravenous drip (100mL:4mg) every 4 weeks
Study NCT05684432 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06791564 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AVELI
Description: Minimally invasive method for selectively identifying and manually releasing specific septa responsible for causing cellulite depressions.